Tags

Type your tag names separated by a space and hit enter

K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer.
Eur J Surg Oncol. 2010 Jul; 36(7):657-62.EJ

Abstract

OBJECTIVE

To determine the prognostic value of K-ras mutations in plasma DNA of unresectable pancreatic cancer patients.

METHODS

Blood samples were collected from 91 patients with unresectable pancreatic cancer prior to treatment. K-ras gene was amplified from the circulating plasma DNA. Mutations were detected by direct sequencing. The relationship between the types of K-ras gene and prognosis of unresectable pancreatic cancer was evaluated.

RESULTS

K-Ras codon 12 mutations were found in 30 of 91(33%) plasma DNA samples, 17mutations were c.35G>A (p.G12D), 11 were c.35G>T (p.G12V) and only 2 were c.34G>C (p.G12R)). K-ras codon 12 mutations could significantly reflect the clinical parameters, including TNM tumor staging (P=0.033) and liver metastasis (P=0.014). The median survival time of patients with K-ras mutations was shorter than that of patients with wild-type K-ras gene (3.9 months vs. 10.2 months, P<0.001). K-ras codon 12 mutation from plasma DNA was an independent negative prognostic factor for survival (hazard ratio, 7.39; 95% confidence interval, 3.69-14.89).

CONCLUSION

K-ras mutation in plasma DNA is a predictive biomarker for a poor prognosis of unresectable pancreatic cancer patients.

Authors+Show Affiliations

Department of Hepatobiliary & Pancreatic Oncology, Cancer Hospital, Fudan University, Shanghai, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20542658

Citation

Chen, H, et al. "K-ras Mutational Status Predicts Poor Prognosis in Unresectable Pancreatic Cancer." European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, vol. 36, no. 7, 2010, pp. 657-62.
Chen H, Tu H, Meng ZQ, et al. K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. Eur J Surg Oncol. 2010;36(7):657-62.
Chen, H., Tu, H., Meng, Z. Q., Chen, Z., Wang, P., & Liu, L. M. (2010). K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 36(7), 657-62. https://doi.org/10.1016/j.ejso.2010.05.014
Chen H, et al. K-ras Mutational Status Predicts Poor Prognosis in Unresectable Pancreatic Cancer. Eur J Surg Oncol. 2010;36(7):657-62. PubMed PMID: 20542658.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. AU - Chen,H, AU - Tu,H, AU - Meng,Z Q, AU - Chen,Z, AU - Wang,P, AU - Liu,L M, Y1 - 2010/06/09/ PY - 2009/09/01/received PY - 2010/04/13/revised PY - 2010/05/10/accepted PY - 2010/6/15/entrez PY - 2010/6/15/pubmed PY - 2010/7/24/medline SP - 657 EP - 62 JF - European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology JO - Eur J Surg Oncol VL - 36 IS - 7 N2 - OBJECTIVE: To determine the prognostic value of K-ras mutations in plasma DNA of unresectable pancreatic cancer patients. METHODS: Blood samples were collected from 91 patients with unresectable pancreatic cancer prior to treatment. K-ras gene was amplified from the circulating plasma DNA. Mutations were detected by direct sequencing. The relationship between the types of K-ras gene and prognosis of unresectable pancreatic cancer was evaluated. RESULTS: K-Ras codon 12 mutations were found in 30 of 91(33%) plasma DNA samples, 17mutations were c.35G>A (p.G12D), 11 were c.35G>T (p.G12V) and only 2 were c.34G>C (p.G12R)). K-ras codon 12 mutations could significantly reflect the clinical parameters, including TNM tumor staging (P=0.033) and liver metastasis (P=0.014). The median survival time of patients with K-ras mutations was shorter than that of patients with wild-type K-ras gene (3.9 months vs. 10.2 months, P<0.001). K-ras codon 12 mutation from plasma DNA was an independent negative prognostic factor for survival (hazard ratio, 7.39; 95% confidence interval, 3.69-14.89). CONCLUSION: K-ras mutation in plasma DNA is a predictive biomarker for a poor prognosis of unresectable pancreatic cancer patients. SN - 1532-2157 UR - https://www.unboundmedicine.com/medline/citation/20542658/K_ras_mutational_status_predicts_poor_prognosis_in_unresectable_pancreatic_cancer_ DB - PRIME DP - Unbound Medicine ER -